What is Precise Bio?
Precise Bio operates at the intersection of biotechnology and advanced manufacturing, specializing in the development of bio-fabricated organs. By leveraging an integrated 3D printing and tissue-engineering platform, the company enables the scalable production of biological tissues derived from a patient's own cells. This methodology significantly mitigates the risks associated with immune rejection and donor shortages. The firm's diverse application portfolio spans critical healthcare verticals, including ophthalmology, cardiology, orthopedics, and dermatology. By providing clinicians with sophisticated tissue engineering tools, Precise Bio is effectively bridging the gap between laboratory research and clinical application, positioning itself as a leader in the next generation of personalized medicine.
How much funding has Precise Bio raised?
Precise Bio has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Precise Bio
PPP
Public-Private Partnership
What's next for Precise Bio?
With this late-stage capital, Precise Bio is well-positioned to accelerate its clinical trial pipelines and scale its manufacturing infrastructure to meet growing demand. The strategic focus will likely shift toward regulatory milestones and the expansion of its proprietary bio-printing technology across international markets. By optimizing its production workflows, the company aims to solidify its market share in the regenerative medicine sector, ultimately transforming the standard of care for patients requiring complex tissue replacement. Future growth will be defined by the successful translation of its bio-fabricated products into routine clinical practice, further validating the commercial viability of its integrated platform.
See full Precise Bio company page
